摘要
目的评估振明正生合剂对人肺癌、大肠癌、神经胶质瘤、肝癌、乳腺癌的抑制作用及其安全性。方法①Balb/c裸鼠分别接种人肺癌细胞系A549、人大肠癌细胞系SW480、人神经胶质瘤细胞系Ln229、人肝癌细胞系L7402和人乳腺癌细胞系MB231,2×10^6只^-1。接种后24 h开始给药,实验组每天口服振明正生合剂0.2 mL/只,连续4周。对照组口服生理盐水0.2 mL/只。每周测量实验组和对照组动物肿瘤大小,计算肿瘤生长抑制率。②振明正生合剂原液浓缩6倍,按照每只小鼠灌胃最大容量,口服浓缩药物0.6 mL/20 g。观察24 h,计算LD50。结果①振明正生合剂对5种人肿瘤裸鼠移植瘤均有明显的抑制肿瘤生长作用。经过3-4周的治疗,该中药对肺癌模型的体积抑制率达到41%（P〈0.05）,对大肠癌模型质量抑制率超过60%（P〈0.05）,对神经胶质瘤模型质量抑制率超过69%（P〈0.05）,对肝癌模型质量抑制率超过79%（P〈0.05）,对乳腺癌模型的质量抑制率达到94%（P〈0.01）。②LD50大于180 mL/kg。结论振明正生合剂对这5种肿瘤模型均有显著的治疗作用,振明正生合剂为无毒/低毒制剂。
Objective It is to evaluate the inhibitive actions of Zhenmingzhengsheng mixture （ZMZS） on human lung cancer, large intestine carcinoma, neuroglioma, liver cancer and breast carcinoma and its safety. Methods ①BALB/c nude mice had inoculations with human pulmonary cancer cell line A549, human large intestine carcinoma cell line SW480, human neuroglioma cell line Ln229, human liver cancer cell line L7402 and human breast carcinoma cell line MB231 with 2×10^6/ mouse. After inoculation for 24 hours, experiment group was administered ZMZS 0.2 mL/mouse taken orally every for four weeks and control group was administered physiological saline 0.2 mL/mouse taken orally. The sizes of tumor in the two groups were measured weekly and the inhibitive rate of tumor growth was calculated. ②The original liquid of ZMZS was concentrated to 1/6. According the most dosage of one mouse can be received intragastric administration, the concentrates 0. 6 mL/20 g was taken orally. The mice were observed for 24 hours and the LD50 was calculated. Results ①The ZMZS had obvious inhibitive actions on tumor growth of nude mice transplanted tumor with all the five kinds of human tumor cell. Through therapy for three to four weeks, the volume inhibition rate of ZMZS on lung cancer models were 41% （P 〈 0.05）, the mass inhibition rate of ZMZS on large intestine carcinoma models exceeded 60 % （P 〈 0.05）, the mass inhibition rate of ZMZS on neuroglioma models exceeded 69 % （ P 〈 0.05 ）, the mass inhibition rate of ZMZS on liver cancer models exceeded 79 % （P〈 0.05） and the mass inhibition rate of ZMZS on breast carcinoma models exceeded 94 % （P 〈0.05）. ② The LD50 was larger than 180 mL/kg. Conclusion The ZMZS has significant therapeutic action on the five tumor models. The ZMZS is atoxic/harmfulless praeparatum.
出处
《现代中西医结合杂志》
CAS
2009年第14期1593-1597,共5页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
振明正生合剂
人肿瘤细胞裸鼠移植瘤
抑制率
急性毒性试验
LD50
Zhenmingzhengsheng mixture
nude mice transplanted tumor with human tumor cell
inhibitive rate
acute toxicity test
LD50
